Company profilePharmaceutical#450 of 1,318 in Pakistan1 DRAP alert

OBS Pharma (Pvt) Ltd

Pharmaceutical company · 34 brands · 46 molecules

Ranked #79 of 156 companies in Antianemic, Iron Preparations

34 registered products 18 pharmaceutical brands 46 distinct molecules 1 DRAP alert

Company overview

34
registered products
18
pharmaceutical brands
46
distinct molecules
12
therapeutic classes
1
DRAP alerts

OBS Pharma (Pvt) Ltd is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 34 product registrations across 46 distinct molecules. Its portfolio is concentrated in Antianemic, Iron Preparations and Gonadotropins And Other Ovulation Stimulants. DRAP has issued 1 alert involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by OBS

17 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Antiinflammatory And Antirheumatic Products 1

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

4
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
20264

Top molecules by brand count

Therapeutic classes

Antianemic, Iron Preparations · 2Gonadotropins And Other Ovulation Stimulants · 2Anti-Infectives · 2Antifungal For Dermatological · 2Antineoplastics · 2Antibiotics For Topical Use · 2Hormone Regulators · 2Immunostimulants · 1Neuro · 1Psycholeptics; Antipsychotics, Anxiolytics, Hypnotics And Sedatives · 1Drugs For Obstructive Airway Diseases, Systemic · 1Quinolone Antibacterials · 1

Conditions treated

Anxiety/Depression/Insomnia · 1General Infections · 1Fungal Infection · 1Infertility · 1Contraceptives · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official16 products · Rs 134.79 – Rs 102,238.25
DVAGO9 products · Rs 74.3 – Rs 750
Servaid6 products · Rs 193.86 – Rs 525
Median across source: Rs 410

Regulatory record

1 alert in the DRAP feed we track.

Rapid Alert; Drug Product: Falsified Ciproxin 500mg Tablets identified in the Market
2023-06-20

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

BOSCH PHARMACEUTICALS (PVT) LTD. holds 153 molecules not in this portfolio
AmikacinAmlodipineAmoxicillinAmoxicillin SodiumAmoxicillin …50Mg Clavulanic Acid 12.5 MgAmoxycillin
SHAIGAN PHARMACEUTICALS (PVT) LTD. holds 136 molecules not in this portfolio
AlbendazoleAmikacinAmlodipineAmlodipine BasylateArtemetherAscorbic Acid
Pfizer Laboratories (Pvt) Ltd. holds 132 molecules not in this portfolio
AlprazolamAluminium HydroxideAluminium Hydroxide And OxideAmlodipineAmodiaquineAmodiaquine Base

Get the full profile for OBS

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.